Background. Although arteriovenous fistulas (AVFs) are actively promoted, their use at the start of haemodialysis (HD) seems to be decreasing worldwide. In this paper, we describe recent trends in incidence and prevalence of vascular access types in Europe from 2005 to 2009 and their relationship with patient characteristics and survival. Methods. Ten European renal registries participating in the ERA-EDTA Registry provided data on incidence (n = 13 044) and/or prevalence (n = 75 715) of vascular access types. We used logistic regression to assess which factors influence the likelihood to be treated with an AVF rather than another type. Results. The use of AVFs at the start of HD showed a significant decreasing trend from 42% in 2005 to 32% in 2009 (P < 0.0001), while the use of central venous catheters (CVCs) increased from 58 to 68% (P < 0.0001). A similar evolution pattern was observed for the prevalence; use of AVFs decreased from 66 to 62% and use of CVCs increased from 28 to 32%. There was a large international variation in the use of the
catheters (CVCs) and surgically created arteriovenous access types, i.e. native arteriovenous fistulas (AVFs) and synthetic arteriovenous grafts (AVGs). Of these vascular access types, CVCs and AVFs are most commonly used in Europe.
Although randomized controlled trials comparing different types of access are lacking, national programs and scientific society guidelines such as the Kidney Diseases Outcomes Quality Initiative (K/DOQI) and European Renal Best Practice (ERBP) Guidelines strongly promote the use of AVFs and discourage the use of catheters [1, 2] . This fistula first (and catheter last) policy is based on evidence from large observational studies showing that the use of AVFs is associated with the lowest (and catheters with the highest) risk of death from infection and cardiovascular disease [3, 4] . However, the proportion of elderly HD patients suffering from diabetes and cardiovascular diseases is increasing worldwide. Because in such patient population attainment of a matured AVF may be problematic, use of a CVC becomes inevitable [5] [6] [7] .
In Europe, AVF use has historically been high. Ethier et al. [8] found an initial trend towards reduced use of AVFs between 1996 and 2007 in the European countries included in the Dialysis Outcomes and Practices Patterns Study (DOPPS). However, DOPPS includes a random subsample of the HD patients in each dialysis centre selected for participation and the database is limited to seven countries, which are all located in Western Europe. In the current large registrybased study, data from 10 renal registries in nine countries spread over Europe and representing all dialysis patients in those countries were included to evaluate to which extent use of the different vascular access types changed in the subsequent period among different patient groups. We aimed (i) to assess recent trends in the use of AVFs, AVGs and CVCs at the start (incidence) and after the start of HD ( prevalence) over the 5-year time period from 2005 to 2009 and (ii) to determine whether demographic patient characteristics influenced the use of the different types of vascular access within Europe. In addition, we aimed (iii) to assess survival of patients treated with HD using an AVF as the first vascular access when compared with other vascular access types.
M AT E R I A L S A N D M E T H O D S

Patients
At an annual basis, the ERA-EDTA Registry collects standard data on ESRD patients treated with renal replacement therapy (RRT) from national and regional renal registries in Europe. These data include date of birth, sex, primary renal disease, date of first RRT, treatment history and date and cause of death. In total, 10 renal registries participated in this study by sending additional data on the incidence and/or prevalence of vascular access for HD treatment. Five registries including Austria, FYR of Macedonia, Slovenia, Scotland (UK) and Sweden collected data once per year on the vascular access in use among prevalent HD patients. Denmark collected information on the vascular access type in use among incident patients at the start of HD (Day 1 of treatment). In addition, four registries including Belgium (French-speaking part), Andalusia (Spain), Catalonia (Spain) and Norway collected data among both prevalent and incident HD patients. In this paper, data on prevalence are predominantly presented for the year 2008, because the most data were available for this year. A complete overview of the data collected is presented in the Supplementary Data. We included all patients 20 years and older who started HD treatment between 2005 and 2009 and for whom data on vascular access were available.
Access type categories and definitions Vascular access type was categorized into four groups: (i) AVF, (ii) AVG, (iii) CVC and (iv) other. The category CVC included both tunnelled (permanent) and non-tunnelled (temporary) catheters because most national and regional registries did not distinguish between those two types. Furthermore, other catheter details, including position (femoral, subclavian or jugular), side (right or left), number of lumina (single or double lumen) and whether the CVC was tunnelled or percutaneous, were unknown in most registries. The category 'other' included various other vascular access types like ports.
Primary renal diseases were defined according to the ERA-EDTA coding system and classified into groups including glomerulonephritis, diabetic nephropathy, renal vascular disease/hypertension, other and unknown [9] . Cardiovascular mortality was defined as death attributable to myocardial ischaemia and infarction, heart failure, cardiac arrest because of other or unknown cause or cerebrovascular accident (ERA-EDTA codes 11, 14-16, 18 and 22). Infectious death was defined as death attributable to pulmonary infection, septicaemia, peritonitis, generalized viral infection and infections elsewhere (ERA-EDTA codes 31-39 and 70) [9] .
Statistical analysis
To explore differences in patient characteristics between the three types of vascular access, we used standard descriptive statistics. To test whether the trends in vascular access type over time were statistically significant, we performed the asymptotic Cochran-Armitage trend test.
Among incident and prevalent HD patients, univariate and multivariate logistic regression analyses were applied to study for different patient groups the likelihood of having an AVF rather than an AVG or CVC. Patients were categorized based on age (i.e. 20-44, 45-59, 60-69, 70-79 or ≥80 years), sex and the presence of diabetic nephropathy, to assess whether these factors influenced the likelihood of receiving an AVF. Results from logistic regression analyses are reported as crude and adjusted odds ratios (ORs) with 95% confidence interval (CI) for the likelihood of receiving an AVF when compared with other vascular access types. The multivariate model included the variables age, sex, presence of diabetic nephropathy and country. For the incident cohort, the multivariate model additionally included the year of HD initiation.
In the group of incident patients, we performed KaplanMeier and Cox proportional-hazard analyses to assess 2-year patient survival (up until 31 December 2011) using an AVF at the start of treatment when compared with an AVG or CVC. We used an intent-to-treat approach whereby patients were classified based on the vascular access type in use at the time of cohort entry (i.e. the day of the first HD run). We studied death from all causes, cardiovascular causes and infectious causes. Follow-up time was censored at recovery of renal function, renal transplantation, loss to follow-up or 31 December 2011, whichever came first. Hazard ratios (HRs) with 95% CI for mortality were calculated using univariable and multivariable Cox regression models, the latter with adjustment for those variables available in the ERA-EDTA Registry: age, sex, primary renal disease, year of HD initiation and country.
All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA, 1999-2001). A two-tailed P-value of <0.05 was considered as statistically significant.
R E S U LT S
Use of vascular access types over time The type of vascular access at the start of HD (incidence) between 2005 and 2009 was reported for a total of 13 044 patients from five countries. As presented in Figure 1a , the majority of the patients started HD using a CVC. This percentage showed an increasing tendency over time, from 58% in 2005 to 68% in 2009 (P for trend <0.0001). Conversely, the use of AVFs as the first vascular access at the start of HD decreased from 42% in 2005 to 32% in 2009 (P < 0.0001). AVGs were used infrequently (<1%) as the first vascular access. Figure 1b presents the prevalence of vascular access types based on the vascular access type reported once a year in nine countries (n = 75 715). When compared with the incidence, the percentage of patients with an AVF was higher among the prevalent than in incident patients. The percentage of patients with an AVF decreased from 66 to 62% over time (P < 0.0001). In contrast, the percentage of CVCs was lower in the prevalent than in the incident group of patients and increased from 28% in 2005 to 32% in 2009 (P < 0.0001). Use of AVGs remained stable over time at 5-6%. Table 1 . Patients with an AVF at the start of HD were significantly younger and less likely of female gender than those with AVGs or CVCs. There were no large differences in the primary cause of renal disease between the vascular access categories, but differences between the countries were substantial. The use of an AVF at HD initiation varied from 24% in Denmark to 48% in Catalonia (Spain), while the use of a CVC varied from 51% in Catalonia (Spain) to 76% in Denmark. The percentage of patients starting HD using an AVG was very low, and in the French-speaking part of Belgium and Denmark AVGs were not used at all. Table 2 summarizes the characteristics of patients prevalent on HD in 2008. In parallel to the incident patients, patients with an AVF were on average younger and less often female than those dialysing with a CVC. In addition, prevalent patients with an AVF less often had diabetes as the primary cause of renal failure. There were very large differences in the use of vascular access types between the countries; CVC use in 2008 was 72% in the French-speaking part of Belgium, while in FYR Macedonia only 6% of the patients had a CVC and 93% an AVF.
Patient characteristics
Figures presenting trends in incidence and prevalence of vascular access types over time for each country separately are provided as Supplementary Data.
Patient characteristics associated with the use of vascular access types
We performed logistic regression analysis to calculate ORs for the likelihood to be treated with an AVF rather than another type of vascular access both in the incident and prevalent patients. As summarized in Table 3 , the multivariable model including the variables age, sex, presence of diabetic nephropathy, year of start HD and country yielded that the likelihood of starting HD using an AVF in incident patients was 20% higher for patients from 45 to 59 years and 23% lower for those ≥80 years when compared with patients of 20-44 years (ORs: 1.20, 95% CI: 1.05-1.37 and 0.77, 95% CI: 0.67-0.90, respectively). For females, the likelihood of starting HD with an AVF was 16% lower when compared with males (OR: 0.84, 95% CI: 0.78-0.90). The presence of diabetic nephropathy and year of start of HD were not associated with the likelihood of having an AVF at the start of HD.
Among the prevalent patients (Table 4) Analysis restricted to countries contributing to both the incident and the prevalent samples [Belgium (French-speaking part), Andalusia (Spain), Catalonia (Spain) and Norway] yielded the same results.
Patient survival
In the 11 003 incident patients for whom data on survival were available, we performed survival analyses to study the association between vascular access type at the start of HD and 2-year patient survival. As presented in Figure 2 , 2-year survival was 82.2% for patients with an AVF, 84.8% for patients with an AVG and 68.8% for patients with a CVC (Log-rank test, P < 0.0001).
In the Cox regression analyses (Table 5) , we found that after adjustment for age, sex, primary renal disease and country, the risk of all-cause mortality was lower in patients using an AVF at the start of HD when compared with patients with an CVC, AVG or other vascular access type (HR: 0.57, 95% CI: 0.52-0.62). Both the risks of cardiovascular (HR: 0.73, 95% CI: 0.64-0.82) and infectious death (HR: 0.58, 95% CI: 0.49-0.69) were reduced for patients with an AVF rather than another type of vascular access. The risk of infectious death 
D I S C U S S I O N
This large multinational registry-based study shows that the use of AVFs at the start of HD in Europe has decreased by 10% in the period between 2005 and 2009, whereas the use of CVCs as initial vascular access increased by 10% to a total of almost 70% over the same time period. A similar, but less pronounced, evolution pattern was observed for prevalent use of vascular access types over time. We found that female patients and patients aged 70 years or older were less likely to start HD with an AVF, while the presence of diabetic nephropathy did not influence the vascular access type used. Mortality was lowest for those patients starting HD with an AVF when compared with those with other vascular access types.
Subgroup analyses
At the start of HD, patients who were treated with an AVF were in general younger and more often male. This is in line with findings from other studies [4, 8] and with data from the United States Renal Data System [10] . An explanation for the finding that women are less often being treated with a AVF may be that maturation of an AVF can be especially problematic in females due to poorer vessels. The fact that women are more often treated with CVCs than with AVFs or AVGs is particularly of interest because we showed that the risk of infectious death was strongly reduced in women starting HD with an AVF when compared with other types of access. Under the assumption of a causal relationship between catheters and infections, this finding implies that further research on the improvement of using AVFs (and potentially also AVGs) in women is needed.
International comparisons
We found pronounced differences between the included European countries, which is in line with previous findings from DOPPS [8, 11] . These differences may be explained by differences in patient characteristics. However, also treatment practices, local policies or health service structure and organization may influence the delivery of vascular access care. In addition, differences in health policy across separate regions or F I G U R E 2 : Kaplan-Meier curves for 2-year survival for categories of vascular access type. Log-rank test, P < 0.0001.
O R I G I N A L A R T I C L E
V a s c u l a r a c c e s s i n E u r o p e even centres may explain variation of vascular access use within a country. The proportion of prevalent patients treated with an AVF in 2008 in our European study was higher than the ∼55% observed in the USA [10] , but lower than the 76% observed in Australia and 67% in New Zealand [12] . The lower proportion of AVFs in the USA can, at least in part, be explained by the higher proportion of prevalent patients with an AVG (13.8%) than in Europe. [10] . However, like in other parts of the world, including Canada [13] , Australia and New Zealand [12] and Japan [14] , only a few of the patients in our study were treated with AVGs. There were even countries, i.e. Denmark and the French-speaking part of Belgium, where AVGs were not used at all. Nevertheless, this option is worth considering as infectious and thrombotic complications, although higher than with AVF, are lower than with CVC [4] . The low number of AVG creations can be problematic because reduced practice may impact performance results. As the creation of AVFs, the AVG surgery may be more complex with the aging of the dialysis population. These factors further reinforce the need of cooperation of different specialties within a vascular access team.
Implications for practice
The declining proportion of AVFs at the start of dialysis led to the AV Fistula First Breakthrough Initiative in the USA (http://www.fistulafirst.org/) in 2009. Similar programmes to promote early AVF creation were started in many countries including Belgium (French-speaking part) and Denmark. The proportion of AVFs at HD initiation is often considered as an indicator for the quality of HD care and as such linked to reimbursement in some countries [15] . An important drawback of this indiscriminate recommendation of the fistula as the ideal vascular access for all patients, however, is that some people will receive several unsuccessful fistula attempts and access-related procedures, with potential discomfort or harm for the patient and inappropriate spending of healthcare budget [7] . This problem could be underestimated, considering that previous studies found that up to 60% of AVFs fail immediately after surgery or fail to mature [5, 16] . Although a recent meta-analysis found a lower overall summary estimate of the risk of primary failure (23%) and an inverse association between the risk of primary failure and publication date, high residual heterogeneity in the analyses raises concerns about the validity of data pooling [17] . In the same meta-analysis, the risk of primary failure was found to be higher in the elderly (37%), the fastest growing group in the dialysis population [17] . Nephrologists may be reluctant to prepare elderly patients for dialysis because many of them may die before starting dialysis at all and as a result these elderly patients more often need a CVC [18] . In addition, elderly patients themselves may have different views of the benefits and harms of a fistula first policy [19] and a recent decision analysis suggests that such an approach may not be the preferred strategy for them [20] .
Whether a nephrologist promotes AVFs may also depend on the availability of appropriate surgical support and access to interventional radiology [21] . Considering the challenges of establishing and maintaining a vascular access, multi-disciplinary access teams have been incorporated into most HD programmes worldwide [1] . Further waiting time for surgical creation has been found to be a barrier for AVF creation [22, 23] . However, none of the registries included in this study reported to have a waiting list for fistula surgery.
Another important factor in AVF creation is the time of referral; whether an AVF is placed pre-emptively or a CVC is inserted often depends on the date of first arrival of patients at the nephrologisty clinic [23] . However, even when a patient is referred to a nephrologist early, the unpredictable nature of late uraemia progression, patient non-compliance and failed fistula creation can hinder planned dialysis start and the use of the intended access.
Finally, we could speculate that the number of patients with an AVF at the start of HD is declining because younger and healthier patients who often have an AVF more often receive a renal transplant and at that moment are censored for further analysis. In addition, patients who receive a pre-emptive transplantation via living donation, who are among those who very likely would receive an AVF, by definition rarely are prepared for HD.
Strengths and limitations
An important strength of the current study is the large sample size and relatively large representation of Europe. Even though only data from 10 renal registries in nine European countries were included in our study, it is very likely that this cohort is representative for the rest of Europe because countries from North (Norway, Denmark and Sweden), South (Spain), Eastern (Slovenia and FYR of Macedonia) and Western Europe [Austria, Belgium and UK (Scotland)] were included. However, it should be noted that the renal registries from large European countries such as France, Italy, UK and Poland could not be included in the study because data on vascular access on an individual patient level were not made available to the ERA-EDTA Registry or not available at all. A second limitation of our study is that it is unknown which definition of vascular access in place was used in the separate centres or registries. Consequently, we do not know exactly what 'prevalent use of AVF' means. For example, a patient could have an AVF in place, but also a CVC because the AVF is not working well. The vascular access type should then be coded as CVC, but possibly some nephrologists coded it as an AVF. The use of CVCs is probably especially high around HD initiation due to an unplanned or unanticipated start of dialysis treatment, which may explain the high percentage of CVCs at the start of HD in some countries like Denmark and Norway. In Denmark, the coding system distinguishes between a temporary CVC, a permanent CVC where a later AVF is planned and a permanent CVC as the patient's permanent vascular access. The high percentage of CVCs recorded at the first dialysis, however, does not necessarily represent vascular access practices in the country, because the majority of patients in the first two groups will later receive an (attempt for an) AVF. We could not differentiate between permanent (tunnelled) and temporary CVCs and it was, therefore, not possible to restrict our survival analyses to patients using permanent catheters. Inclusion of temporary line users, who are often sicker, may have resulted in underestimation of survival probabilities. Another important limitation of our study is that medical and biochemical data, as well as data on comorbidities and pre-dialysis nephrology care, were unavailable, which made extensive multivariate adjustment impossible. As a result, our study suffered from residual confounding. Despite statistical adjustment for the variables that were available, the found associations between vascular access type and patient survival could still be attributed to the fact that patients starting dialysis using a CVC are different from those using an AVF. However, the fact that our findings are similar to those of previous studies using more extensive multivariate models for survival analysis indicates that further adjustment would probably not change our conclusions. Finally, we were not able to study survival of the vascular access in place because data on both vascular access at start of HD and vascular access later during treatment were available for only two registries participating in the study.
CO N C L U S I O N
In conclusion, in Europe there has been a decreasing trend in the use of AVFs and an increasing trend in the use of CVCs at the start of HD between 2005 and 2009. The same trend, although less pronounced, was observed for the use of vascular access types later after dialysis initiation. We cannot explain all of our findings and need to understand why, despite the active promotion of AVF use, it is not possible to increase the actual use of AVFs. In the meantime, we suggest that AVF utilization as an indicator of quality of HD care should be used with caution. Further research is needed to understand key drivers of the choice for a certain vascular access type and how healthcare around vascular access is organized throughout Europe.
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